← The Wire
SGMTNasdaq
Sagimet Biosciences Inc.
Pharmaceutical Preparations · DE · CIK 1400118
Developing novel FASN inhibitors for metabolic and fibrotic diseases like MASH, acne, and cancer
red 8-K · 90d
$400M
Market cap
$7.79
Last close
+10.3%
1D
+9.7%
5D
1.4M
Volume
Price · last 39 sessions-1.4%
May 4L $6.30 · H $8.38Jun 29
82
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GNov 14, 2024SC 13GNEW ENTERPRISE ASSOCIATES 13, L.P. / SAGIMET BIOSCIENCES -- 13GFeb 14, 2024SC 13GSAGIMET BIOSCIENCES INC.Feb 14, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GFeb 14, 2024SC 13GSAGIMET BIOSCIENCES INC.Feb 5, 2024SC 13GSC 13GSep 11, 2023
Insider Activity
In the 90 days to Feb 10, 2026: 5 sold $395K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 10, 2026 | Happel DavidPresident & CEO | Sell | 12,101 | $5.36 | $65K |
| Feb 10, 2026 | Martins Eduardo BrunoChief Medical Officer | Sell | 3,640 | $5.36 | $20K |
| Feb 10, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Sell | 2,622 | $5.36 | $14K |
| Feb 10, 2026 | Chauche ThierryChief Financial Officer | Sell | 1,312 | $5.36 | $7K |
| Nov 20, 2025 | Kemble GeorgeExecutive Chairman | Sell | 37,688 | $7.69 | $290K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance